ライフサイエンスコーパス: cotrimoxazole

1 ed, by household, to continue or discontinue cotrimoxazole.

2 n or to ceftiaxone, and 13 were resistant to cotrimoxazole.

3 tinuing (n = 452) vs discontinuing (n = 384) cotrimoxazole, 0.4 vs 12.2%, respectively, had at least

4 = -2 (adjusted odds ratio, 1.70 vs not using cotrimoxazole [95% confidence interval, 1.28-2.25], P <

5 (28.5%) of isolates were found resistant to cotrimoxazole, ampicillin and chloramphenicol.

6 By univariate analysis, cotrimoxazole and antiretroviral therapy conferred risk

7 >25% became significantly different between cotrimoxazole and non-cotrimoxazole users after 6 months

8 The adjusted mean change in HAZ among cotrimoxazole and non-cotrimoxazole users did not differ

9 on of P. carinii pneumonia prophylaxis (with cotrimoxazole and pentamidine).

10 (76.2%) were susceptible to nitrofurantoin, cotrimoxazole, and cefpodoxime.

11 g resistance (MDR)(resistance to ampicillin, cotrimoxazole, and chloramphenicol), extensive drug resi

12 The use of cotrimoxazole as prophylaxis was associated with an incr

13 e study is limited by uncertain estimates of cotrimoxazole coverage in programmatic settings; an inab

14 Effectiveness of cotrimoxazole (CTX) compared with sulfadoxine-pyrimetham

15 Cotrimoxazole (CTX) discontinuation increases malaria in

16 Cotrimoxazole (CTX) prophylaxis is recommended by the Wo

17 Sulfamethoxazole (SMX) and cotrimoxazole (CTX), a fixed-dose combination of SMX and

18 -T infants) and HEU infants not treated with cotrimoxazole (CTX-N infants).

19 The growth benefits of cotrimoxazole during early antiretroviral therapy (ART)

20 Antenatal provision of cotrimoxazole for HIV-infected pregnant women with low C

21 Cotrimoxazole has antimalarial effects and appears to re

22 While cotrimoxazole has benefits for children with HIV, there

23 monia programs in developing countries where cotrimoxazole is widely used.

24 Antimicrobial prophylaxis consisted of cotrimoxazole, itraconazole, and aciclovir (or valgancic

25 Azithromycin and cotrimoxazole led to an increase in macrolide and sulfon

26 cocci and carriage of PCV7-type pneumococci, cotrimoxazole-nonsusceptible (COT-NS) pneumococci, or pe

27 ated children, the proportion colonized with cotrimoxazole-nonsusceptible pneumococci increased from

28 ated children, the proportion colonized with cotrimoxazole-nonsusceptible pneumococci increased from

29 , unless the patients were prescribed 480 mg cotrimoxazole once daily.

30 ompared to current recommendations, starting cotrimoxazole only after a positive HIV test had the gre

31 sion for 3, 6, 9, or 12 months; and starting cotrimoxazole only for children diagnosed with HIV.

32 participants with advanced HIV randomised to cotrimoxazole or enhanced antimicrobial prophylaxis in t

33 old treated with sulfadoxine/pyrimethamine, cotrimoxazole, or no antimicrobial agent were enrolled i

34 emic antibiotics (azithromycin, amoxicillin, cotrimoxazole, or placebo) on the gut resistome in child

35 Compared to those remaining on cotrimoxazole, patients who discontinued had a relative

36 Cotrimoxazole preventive therapy (CPT) in human immunode

37 Cotrimoxazole preventive therapy (CPT) is recommended fo

38 indicated in HIV-infected women taking daily cotrimoxazole prophylaxis (CTXp) because of potential ad

39 We investigated whether antenatal cotrimoxazole prophylaxis begun during pregnancy for HIV

40 WHO first recommended cotrimoxazole prophylaxis for all infants who are HIV-ex

41 alth Organization (WHO) guidelines recommend cotrimoxazole prophylaxis for children who are HIV-expos

42 is required in HIV-positive women not using cotrimoxazole prophylaxis for opportunistic infections.

43 anges in health care alongside the unchanged cotrimoxazole prophylaxis guidelines and call for a chan

44 -Saharan Africa and who abruptly discontinue cotrimoxazole prophylaxis have an increased incidence of

45 Cotrimoxazole prophylaxis in HEU infants decreased gut m

46 evidence has been generated from the use of cotrimoxazole prophylaxis in infants who are HEU, includ

47 Cotrimoxazole prophylaxis is recommended for subgroups o

48 Cotrimoxazole prophylaxis prolongs survival and prevents

49 Cotrimoxazole prophylaxis was associated with higher non

50 Cotrimoxazole prophylaxis was associated with higher pla

51 Cotrimoxazole prophylaxis was introduced as a routine co

52 confidence interval {CI}, 0.24-0.98]) after cotrimoxazole prophylaxis was introduced than before; th

53 ed with development of nocardiosis; low-dose cotrimoxazole prophylaxis was not found to prevent nocar

54 igher perinatal HIV-exposure rates result in cotrimoxazole prophylaxis.

55 egnant women on antiretroviral treatment and cotrimoxazole prophylaxis.

56 late ART, loss to follow-up, and absence of cotrimoxazole prophylaxis.

57 ite, maternal education, economic level, and cotrimoxazole prophylaxis.

58 igher perinatal HIV exposure rates result in cotrimoxazole prophylaxis.

59 e greater in those receiving enhanced versus cotrimoxazole prophylaxis.

60 maintaining current recommendations; shorter cotrimoxazole provision for 3, 6, 9, or 12 months; and s

61 Changing current guidelines from universal cotrimoxazole provision for children who are HIV-exposed

62 d to see if either increases the carriage of cotrimoxazole-resistant Streptococcus pneumoniae in Mala

63 we model the potential impact of alternative cotrimoxazole strategies on mortality in children who ar

64 can help inform policymaker deliberations on cotrimoxazole strategies, recognising that the risks and

65 e and compared microbiome signatures between cotrimoxazole treated HEU infants (CTX-T infants) and HE

66 For cotrimoxazole-treated children, the proportion colonized

67 Prophylactic cotrimoxazole treatment is recommended in HIV exposed, u

68 Prophylactic cotrimoxazole treatment is recommended in human immunode

69 to not receive (n = 29; CTX-N) prophylactic cotrimoxazole treatment.

70 (n=34) or to not receive (n=29) prophylactic cotrimoxazole treatment.

71 sted but was attenuated when modelling lower cotrimoxazole uptake, smaller mortality benefits, higher

72 Cotrimoxazole use is associated with benefits to WAZ but

73 In those underweight (WAZ < -2) at baseline, cotrimoxazole use was associated with a follow-up WAZ >/

74 ren who were stunted (HAZ < -2) at baseline, cotrimoxazole use was not associated with a follow-up HA

75 Cotrimoxazole use was not associated with a significant

76 ntly different between cotrimoxazole and non-cotrimoxazole users after 6 months of ART and remained s

77 an change in HAZ among cotrimoxazole and non-cotrimoxazole users did not differ significantly over th

78 sistance to ampicillin, chloramphenicol, and cotrimoxazole was 38.11%, with regional differences in s

79 ver injury due to antiretroviral therapy and cotrimoxazole was a frequent clinicopathological finding

80 In multivariate analysis, cotrimoxazole was associated with a cholestatic or ducto

81 Low-dose cotrimoxazole was not found to prevent Nocardia infectio

82 fections with trimethoprim/sulfamethoxazole (cotrimoxazole) was assessed to see if either increases t

83 Oral amoxicillin and cotrimoxazole were widely available at low cost in most

84 ing antiretroviral therapy (ART) discontinue cotrimoxazole when CD4 counts are >200 cells/muL.

85 herichia coli), only 24% were susceptible to cotrimoxazole, whereas 90% were susceptible to ciproflox